Wednesday, 12 Dec 2018

You are here

Elder Rheumatoids Less Likely to Receive Biologics

Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients. Now a VAMC study shows that the elderly are less likely to receive biologic agents yet are as likely to be subjected to glucocorticoid use.

A study using national US Veteran’s Affairs databases between 2005–2016 identified RA patients after their first-ever methotrexate (MTX) therapy and analyzed subsequent drug use. 

From 17,415 patients on MTX, 3263 received biologic therapy within 2 years (20.6% 2-yr incidence).  The rate of biologic use was significantly lower in older patients (aHR 0.20; 95% CI 0.16, 0.26) when comparing those ≥ 80 vs < 50 years of age. 

RA patients with comorbidities were less likely to receive biologic agents (aHR 0.79; 95% CI 0.72, 0.87) when comparing those with a Charlson score ≥ 3 vs < 3. Similarly, biologics were less often used in those with heart failure (aHR 0.68), cancer (aHR 0.78) or in nonwhite (aHR 0.79) individuals.

However, glucocorticoid use was similar across age groups and more common in patients with greater comorbidity.

This pattern of drug use in the elderly suggests practitioners are more likely to subject the elderly to more toxic glucocorticoids than to biologics, largely because of their age or confounding comorbidities.  

It is worth noting that current treatment guidelines for RA, do not discourage or encourage best practices based on age or even comorbidity limits. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

I wonder if the researchers bothered to consider the financial aspect of this question. People on government-assisted programs such as Medicare and Medicaid do not have access to co-pay assistance programs from the manufacturers. Cost is the primary factor my patients on Medicare consider before proceeding with a biologic agent.

More Like This

CV Risks Similar in Systemic Sclerosis and Rheumatoid Arthritis

Interactions between disease-related inflammatory processes and the development of several morbidities have been well-studied in RA, particularly heart disease. This is not the case for the often-lethal SSc (estimated standardized mortality ratio between 2.5 and 4.0). Similarly, there are no studies comparing the most relevant comorbidities between SSc and RA.

PRAIRI Study - Can RA Be Prevented?

B-cell depletion may offer a means of delaying the onset of clinical arthritis in adults at high risk, according to the PRAIRI study - a proof-of-mechanism study in pre-clinical RA patients. 

Rheumatoid Lung Disease Imposes Significant Morbidity and Mortality

Insurance claims data were analyzed for the frequency of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA) and finds that although rare, its frequency increased over time and it is associated with a significant mortality rate. 

The study was done because RA-ILD has been shown to cause significant morbidity and mortality. 

Growing Tick Population Comes with Health Concerns

CNN has published a recent government report from the Tick-Borne Disease Working Group that suggests the US tick population is growing and may bring with it an increase in tick-related illnesses. 

While Lyme disease is the most popular of tick-borne illnesses, there are another 20 known conditions related to tick bites.

Chikungunya Virus Vaccine Developed

Lancet reports on a new vaccine for Chikungunya fever (MV-CHIK) demonstraing excellent safety, tolerability and good immunogenicity, independent of pre-existing immunity against the vector. MV-CHIK is a promising vaccine for the prevention of chikungunya fever.